Arkadios Wealth Advisors Boosts Holdings in Merck & Co., Inc. (NYSE:MRK)

Arkadios Wealth Advisors grew its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 8.7% during the 2nd quarter, HoldingsChannel reports. The fund owned 15,475 shares of the company’s stock after acquiring an additional 1,233 shares during the quarter. Arkadios Wealth Advisors’ holdings in Merck & Co., Inc. were worth $1,411,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in MRK. Bromfield Sneider Wealth Advisors bought a new position in shares of Merck & Co., Inc. in the first quarter worth approximately $79,000. Hikari Power Ltd grew its holdings in shares of Merck & Co., Inc. by 5.0% in the first quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock worth $1,939,000 after purchasing an additional 1,130 shares during the last quarter. Financial Management Professionals Inc. grew its holdings in shares of Merck & Co., Inc. by 9.3% in the second quarter. Financial Management Professionals Inc. now owns 3,414 shares of the company’s stock worth $311,000 after purchasing an additional 291 shares during the last quarter. ACG Wealth grew its holdings in shares of Merck & Co., Inc. by 5.6% in the first quarter. ACG Wealth now owns 13,523 shares of the company’s stock worth $1,110,000 after purchasing an additional 722 shares during the last quarter. Finally, Mascoma Wealth Management LLC grew its holdings in shares of Merck & Co., Inc. by 36.4% in the first quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock worth $76,000 after purchasing an additional 247 shares during the last quarter. 73.33% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

MRK opened at $87.51 on Friday. The stock has a 50-day moving average price of $88.83 and a 200-day moving average price of $87.81. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15. The firm has a market cap of $221.69 billion, a PE ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33. Merck & Co., Inc. has a 1 year low of $71.50 and a 1 year high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.20. The firm had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. Merck & Co., Inc.’s quarterly revenue was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.31 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 42.27%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MRK. Atlantic Securities raised their target price on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Berenberg Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and lifted their price target for the company from $95.00 to $100.00 in a report on Wednesday, September 14th. UBS Group lifted their price target on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the company a “neutral” rating in a report on Monday, July 18th. SVB Leerink lifted their price target on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a report on Monday, September 12th. Finally, Cowen lifted their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Monday, June 27th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.